Vk 2735 News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Vk 2735. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Vk 2735 Today - Breaking & Trending Today
The enticing prospect – and proven worth – of dually agonizing the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors gained more evidence in a big way from Viking Therapeutics Inc. with VK-2735 in a phase II weight loss study. Shares of San Diego-based Viking Therapeutics Inc. (NASDAQ:VKTX) closed Feb. 27 at $85.05, up $46.57, or 121%, as investors learned that the drug achieved the primary and all secondary endpoints in the phase II study called Venture, with significant body-weight drops at all doses compared to placebo. ....